Search

Coloplast A-S (Class B)

Закрыт

552.6 1.02

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

541.2

Макс.

558

Ключевые показатели

By Trading Economics

Доход

70M

875M

Продажи

2M

7B

P/E

Средняя по отрасли

33.486

89.037

Прибыль на акцию

3.88

Дивидендная доходность

4.24

Рентабельность продаж

12.572

Сотрудники

16,744

EBITDA

2B

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+11.86% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

4.24%

2.18%

Следующий отчет о доходах

6 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-947M

122B

Предыдущая цена открытия

551.58

Предыдущая цена закрытия

552.6

Coloplast A-S (Class B) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 янв. 2026 г., 21:55 UTC

Отчет

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 янв. 2026 г., 23:52 UTC

Отчет

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 янв. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 янв. 2026 г., 23:42 UTC

Обсуждения рынка

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 янв. 2026 г., 23:40 UTC

Обсуждения рынка

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 янв. 2026 г., 23:30 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

22 янв. 2026 г., 23:30 UTC

Обсуждения рынка

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 янв. 2026 г., 22:37 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 янв. 2026 г., 21:59 UTC

Приобретения, слияния, поглощения

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

22 янв. 2026 г., 21:44 UTC

Отчет

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 янв. 2026 г., 21:32 UTC

Приобретения, слияния, поглощения

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 янв. 2026 г., 21:31 UTC

Приобретения, слияния, поглощения

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 янв. 2026 г., 21:31 UTC

Приобретения, слияния, поглощения

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 янв. 2026 г., 21:30 UTC

Отчет

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

Capital One To Acquire Brex >COF

22 янв. 2026 г., 21:13 UTC

Отчет

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 янв. 2026 г., 21:11 UTC

Отчет

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 янв. 2026 г., 21:11 UTC

Отчет

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 янв. 2026 г., 21:10 UTC

Отчет

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 янв. 2026 г., 21:06 UTC

Отчет

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Rev $15.58B >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q EPS $3.26 >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Net Interest Margin 8.26% >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Net $2.13B >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Adj EPS $3.86 >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Capital One 4Q Net Charge-Offs $3.8B >COF

22 янв. 2026 г., 21:05 UTC

Отчет

Intuitive Surgical 4Q EPS $2.21 >ISRG

Coloplast A-S (Class B) Прогноз

Целевая цена

By TipRanks

11.86% рост

Прогноз на 12 месяцев

Средняя 901.38 DKK  11.86%

Максимум 1,056 DKK

Минимум 720 DKK

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Coloplast A-S (Class B) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

8 ratings

2

Покупка

4

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat